Veriton recently launched its first product in Australia, Zyamis developed by Origin, is a novel epilepsy drug indicated for the treatment of children.
In addition, Origin created the name Seglentis (a treatment for acute pain in adults) for ESTEVE, which was recently approved by the FDA and represents the company’s first product to be launched in the USA. On top of which it is also a new chemical entity, having no prior regulatory precedent for the evaluation and classification of this type of active ingredient.